These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36736154)

  • 21. Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.
    Ibrahim HS; Abdelsalam M; Zeyn Y; Zessin M; Mustafa AM; Fischer MA; Zeyen P; Sun P; Bülbül EF; Vecchio A; Erdmann F; Schmidt M; Robaa D; Barinka C; Romier C; Schutkowski M; Krämer OH; Sippl W
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.
    Guzman ML; Yang N; Sharma KK; Balys M; Corbett CA; Jordan CT; Becker MW; Steidl U; Abdel-Wahab O; Levine RL; Marcucci G; Roboz GJ; Hassane DC
    Mol Cancer Ther; 2014 Aug; 13(8):1979-90. PubMed ID: 24934933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
    Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
    Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy.
    Raouf YS; Sedighi A; Geletu M; Frere GA; Allan RG; Nawar N; de Araujo ED; Gunning PT
    J Med Chem; 2023 Dec; 66(24):16658-16679. PubMed ID: 38060537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.
    Ashwini N; Garg M; Mohan CD; Fuchs JE; Rangappa S; Anusha S; Swaroop TR; Rakesh KS; Kanojia D; Madan V; Bender A; Koeffler HP; Basappa ; Rangappa KS
    Bioorg Med Chem; 2015 Sep; 23(18):6157-65. PubMed ID: 26299825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
    Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
    Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
    Matthews GM; Mehdipour P; Cluse LA; Falkenberg KJ; Wang E; Roth M; Santoro F; Vidacs E; Stanley K; House CM; Rusche JR; Vakoc CR; Zuber J; Minucci S; Johnstone RW
    Blood; 2015 Nov; 126(21):2392-403. PubMed ID: 26447190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis.
    Zhang J; Gao X; Wei M; Li Y; Yang G; Yang C; Yu L
    Clin Sci (Lond); 2021 Jul; 135(14):1751-1765. PubMed ID: 34282832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
    Yan B; Chen Q; Shimada K; Tang M; Li H; Gurumurthy A; Khoury JD; Xu B; Huang S; Qiu Y
    Leukemia; 2019 Apr; 33(4):931-944. PubMed ID: 30291336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
    Mims A; Walker AR; Huang X; Sun J; Wang H; Santhanam R; Dorrance AM; Walker C; Hoellerbauer P; Tarighat SS; Chan KK; Klisovic RB; Perrotti D; Caligiuri MA; Byrd JC; Chen CS; James Lee L; Jacob S; Mrózek K; Bloomfield CD; Blum W; Garzon R; Schwind S; Marcucci G
    Leukemia; 2013 Apr; 27(4):871-8. PubMed ID: 23178755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of class I and II histone deacetylase gene expression in human leukemia.
    Yang H; Maddipoti S; Quesada A; Bohannan Z; Cabrero Calvo M; Colla S; Wei Y; Estecio M; Wierda W; Bueso-Ramos C; Garcia-Manero G
    Leuk Lymphoma; 2015; 56(12):3426-33. PubMed ID: 25944469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
    [No Abstract]   [Full Text] [Related]  

  • 39. Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
    Huang Y; Dong G; Li H; Liu N; Zhang W; Sheng C
    J Med Chem; 2018 Jul; 61(14):6056-6074. PubMed ID: 29940115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment and Characterization of Long-Term Cultures Derived from Primary Acute Myeloid Leukemia Cells for HDAC Inhibitor Research.
    Romanski A; Bug G
    Methods Mol Biol; 2017; 1510():127-148. PubMed ID: 27761818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.